Cannabis Investments

Medical Marijuana Frontier, Cannabis Science Brand Extracts Successful Cancer Treatments Confirmed as Squamous Cell Carcinoma and Skin Cancer Patients Report Continued Shrinking of Cancer Cells

January 6, 2012

NEWPORT BEACH, Calif., /PRNewswire/ — We stumbled upon this news a couple weeks back regarding Cannabis Science, Inc. (OTCBB:CBIS.OB) reported the continuing successful progress by two patients who have been topically self-administering Cannabis Science extracts for Squamous Cell Carcinoma Cancer and Skin Cancer.

According to their earlier press releases, these patients have photo-documented dramatic results that the Company will release to the public once treatment is completed and has been properly vetted by clinical biopsy. The Company, in conjunction with several Colorado-licensed dispensaries and physicians, consults with a number of cancer patients who are seeking to inform themselves of the current peer-reviewed scientific literature, regarding modern and historical use of cannabis preparations for treating cancers so that they can make informed decisions regarding their self-directed cancer treatment.

Cannabis has an outstanding safety profile as determined in 1988 by Federal Administrative Law Judge Francis Young who recommended cannabis be removed from Schedule I. The refusal of the DEA to follow this recommendation has resulted in 16 states allowing some form of medical marijuana access for their citizens. Numerous other states are moving in this direction. Consequently, patients in states with medical marijuana laws are able to make an informed decisions to try various state-legal cannabis preparations and to determine what is most effective for their particular condition. As a result, there is an unprecedented accumulation of “anecdotal” data.

Cannabis Science went on to mention that it’s making cannabis-based medicines available to the public as rapidly as possible. The Company is taking multiple approaches to accomplishing this aim in the United States. The science of cannabinoids has exploded over the past decade, laying the scientific foundation for the many medicinal uses of this unique plant. Cannabinoids are a class of biologically active compounds produced by all vertebrates (endocannabinoids) the Cannabis plant (phytocannabinoids), and more recently patentable synthetic compounds produced by chemists. Today’s modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.

Also, the Company has already released its first two Cannabis Science Brand Formulations, Cannabis Science CT-1 and Cannabis Science MT-1. Both are now available at both Cannabis Therapeutics and Marisol Therapeutics exclusively for Colorado State licensed medical marijuana patients.

Cannabis Science MT-1: Produced by Marisol Therapeutics: A family-owned shop, Marisol Therapeutics was founded to assist medical marijuana patients in obtaining medical marijuana in Colorado. They believe patients have the right to safe, confidential, quality medical marijuana and products. They recommend medical marijuana from their own experience with unrelenting and previously untreatable pain. “We understand, we care, we want you to heal.” Marisal Therapeutics has produced a custom blend that is derived from their proprietary strains that were developed over 30 years by a Native American Vietnam veteran in order to address his medical needs. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds. The product is produced in soil under organic roof conditions.

ADDRESS: 922 Kimble Drive, Pueblo West, CO 81007
PHONE: 719-547-4000
EMAIL: info@marisolmed.com or http://marisolmed.com/ for more information.

Cannabis Science CT-1: Produced by Cannabis Therapeutics was Colorado’s first dispensary. Working with local law enforcement, state officials, legal experts, medical physicians, and researchers, Cannabis Therapeutics sets a standard of both safety and consistent quality to its members as well as the community at large. Cannabis Therapeutics is a professional medical business that employs all its policies and regulations to ensure the most stringent adherence to the law. Second in importance to legality is implementation of standardizing techniques to ensure both repeatability in dosing and quality of medicine. Cannabis Therapeutics began as an organization built by individuals that did not receive satisfactory relief from conventional therapies. Cannabis Therapeutics has produced a high quality cannabis extract from a custom blend of buds hydroponically grown medical marijuana strains. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds.

ADDRESS: 907 E Fillmore St., Colorado Springs, CO 80907
http://www.cannabistherapeutics.net/ for more information.

Please visit www.cannabisscience.com to view the “Breaking News” of the successful results and images of the self-administered cancer treatments.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

View full post on News Releases

www.shcri.com – Chinese textile industry consists of cotton and chemical fiber weaving , printing & dyeing and finishing, wool weaving, dyeing and finishing, hemp weaving, silk weaving and finish machining, as well as the production of cotton, chemical fiber, wool, hemp and silk products. It has to be pointed out that Chinese textile industry does not include clothing manufacturing.

Chinese textile industry has been in recovery from the downturn of January and February of 2009. A number of indexes in 2009Q2 indicate that Chinese textile industry has begun to recover. From January to May of 2009, the sales revenue of Chinese textile industry was RMB 781.296 billion, rising by 5.16% YOY. At the end of May 2009, the asset in Chinese textile industry was RMB 1.468828 trillion, increasing by 7.9% YOY; the number of enterprises was 31,459, rising by 2,944 YOY.

At the end of May 2009, the sales revenue per capita of Chinese textile industry was RMB 133,400, rising by RMB 7,800 YOY. The asset per capita was RMB 250,800, increasing by 20,000 YOY. The sales revenue per company was RMB 24.8354 million, reducing by RMB 1.9105 million YOY. The asset per company was RMB 46.6902 million, decreasing by RMB 2.4643 million YOY.

Chinese government has strengthened the investment since 2009. Thus the fixed asset investment in the textile industry sees slight recovery. In 2009H1, the fixed asset investment in Chinese textile industry was RMB 78.081 billion, rising by 7% YOY. From January to May, the quantity of projects with over RMB 5 million (included) fixed asset investment was 5,766, rising by 2.98% YOY.

In 2009H1, the output of Chinese yarn was 10.962 million tons, rising by 9.40% YOY. The outputs of Shandong, Jiangsu, Henan, Zhejiang and Fujian ranked among the Top 5. The aggregate output of the five regions took up 73.75% of that in China.

In 2009H1, the output of Chinese cloth was 25.8 billion meters, rising by 0.20% YOY. The outputs of Zhejiang, Shandong, Jiangsu, Hubei and Hebei ranked among the Top 5. The aggregate production of the five regions accounted for 75.66% of that in China.

In 2009H1, the output of Chinese cotton cloth was 14.58 billion meters, increasing by 1.70% YOY. The outputs of Shandong, Jiangsu, Hubei, Hebei and Henan ranked among the Top 5. The aggregate production of the five regions took up 76.67% of that in China.

In 2009H1, the output of Chinese pure chemical fiber cloth was 7.04 billion meters, decreasing by 0.4% YOY. The outputs of Zhejiang, Jiangsu, Fujian, Shandong and Guangdong ranked among the Top 5. The aggregate production of the five regions took up 94.20% of that in China.

In 2009H1, the output of Chinese printing and dyeing cloth was 24.227 billion meters, rising by 3.38% YOY. The outputs of Zhejiang, Jiangsu, Guangdong, Shandong and Fujian ranked among the Top 5. The aggregate production of the five regions accounted for 89.84% of that in China.

In 2009H1, the output of Chinese cord fabric was 227,700 tons, increasing by 0.37% YOY. The outputs of Jiangsu, Shandong, Zhejiang, Henan and Anhui ranked among the Top 5. The aggregate production of the five regions took up 95% of that in China.

In 2009H1, the output of Chinese yarn-dyed fabric was 919.5949 million meters, rising by 9.36% YOY. The outputs of Jiangsu, Shandong, Zhejiang, Hunan and Guangdong ranked among the Top 5. The aggregate production of the five regions took up 84.90% of that in China.

Through this report, readers can acquire more information:

-Operation of Chinese textile industry, 2008-2009

-Output of Chinese cloth, 2008-2009H1

-Output of Chinese cotton cloth, 2008-2009H1

-Output of Chinese yarn, 2008-2009H1

-Import and export of Chinese cotton woven fabric, 2008-2009H1

-Import and export of Chinese silk fabric, 2008-2009H1

-Main events in Chinese textile industry, 2008-2009

-Prediction on the development of Chinese textile industry, 2009-2010

Following persons are recommended to buy this report:

-Textile enterprises

-Clothing manufacturers

-Textile and clothing distributors

-Cotton, wool and silk suppliers

-Investors concerning Chinese textile industry

-Research institutions concerning Chinese textile industry

-Others concerning Chinese textile industry

Source: China Research and Intelligence

If you’d like to copy or quote this article, please keep the source information

More information can be browsed:

http://www.shcri.com/reportdetail.asp?id=381

Contacts:

Eileen Gu

Sales Manager

China Research and Intelligence

www.shcri.com

Email: eileen@shcri.com

TEL: 86-21-6852-1029 ext.601  

86-21-6150-9706

FAX: 86-21-6852-1029 ext.604

Chinese textile industry consists of cotton and chemical fiber weaving , printing & dyeing and finishing, wool weaving, dyeing and finishing, hemp weaving, silk weaving and finish machining, as well as the production of cotton, chemical fiber, wool, hemp and silk products. It has to be pointed out that Chinese textile industry does not include clothing manufacturing.
Chinese textile industry has been in recovery from the downturn of January and February of 2009. A number of indexes in 2009Q2 indicate that Chinese textile industry has begun to recover. From January to May of 2009, the sales revenue of Chinese textile industry was RMB 781.296 billion, rising by 5.16% YOY. At the end of May 2009, the asset in Chinese textile industry was RMB 1.468828 trillion, increasing by 7.9% YOY; the number of enterprises was 31,459, rising by 2,944 YOY.
At the end of May 2009, the sales revenue per capita of Chinese textile industry was RMB 133,400, rising by RMB 7,800 YOY. The asset per capita was RMB 250,800, increasing by 20,000 YOY. The sales revenue per company was RMB 24.8354 million, reducing by RMB 1.9105 million YOY. The asset per company was RMB 46.6902 million, decreasing by RMB 2.4643 million YOY.
Chinese government has strengthened the investment since 2009. Thus the fixed asset investment in the textile industry sees slight recovery. In 2009H1, the fixed asset investment in Chinese textile industry was RMB 78.081 billion, rising by 7% YOY. From January to May, the quantity of projects with over RMB 5 million (included) fixed asset investment was 5,766, rising by 2.98% YOY.
In 2009H1, the output of Chinese yarn was 10.962 million tons, rising by 9.40% YOY. The outputs of Shandong, Jiangsu, Henan, Zhejiang and Fujian ranked among the Top 5. The aggregate output of the five regions took up 73.75% of that in China.

For more information please contact :

http://www.aarkstore.com/reports/Research-Report-on-Chinese-Textile-Industry-2008-2009-32797.html
http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
URL: www.aarkstore.com

Chinese textile industry consists of cotton and chemical fiber weaving , printing & dyeing and finishing, wool weaving, dyeing and finishing, hemp weaving, silk weaving and finish machining, as well as the production of cotton, chemical fiber, wool, hemp and silk products. It has to be pointed out that Chinese textile industry does not include clothing manufacturing.
Chinese textile industry has been in recovery from the downturn of January and February of 2009. A number of indexes in 2009Q2 indicate that Chinese textile industry has begun to recover. From January to May of 2009, the sales revenue of Chinese textile industry was RMB 781.296 billion, rising by 5.16% YOY. At the end of May 2009, the asset in Chinese textile industry was RMB 1.468828 trillion, increasing by 7.9% YOY; the number of enterprises was 31,459, rising by 2,944 YOY.
At the end of May 2009, the sales revenue per capita of Chinese textile industry was RMB 133,400, rising by RMB 7,800 YOY. The asset per capita was RMB 250,800, increasing by 20,000 YOY. The sales revenue per company was RMB 24.8354 million, reducing by RMB 1.9105 million YOY. The asset per company was RMB 46.6902 million, decreasing by RMB 2.4643 million YOY.
Chinese government has strengthened the investment since 2009. Thus the fixed asset investment in the textile industry sees slight recovery. In 2009H1, the fixed asset investment in Chinese textile industry was RMB 78.081 billion, rising by 7% YOY. From January to May, the quantity of projects with over RMB 5 million (included) fixed asset investment was 5,766, rising by 2.98% YOY.
In 2009H1, the output of Chinese yarn was 10.962 million tons, rising by 9.40% YOY. The outputs of Shandong, Jiangsu, Henan, Zhejiang and Fujian ranked among the Top 5. The aggregate output of the five regions took up 73.75% of that in China.
In 2009H1, the output of Chinese cloth was 25.8 billion meters, rising by 0.20% YOY. The outputs of Zhejiang, Shandong, Jiangsu, Hubei and Hebei ranked among the Top 5. The aggregate production of the five regions accounted for 75.66% of that in China.
In 2009H1, the output of Chinese cotton cloth was 14.58 billion meters, increasing by 1.70% YOY. The outputs of Shandong, Jiangsu, Hubei, Hebei and Henan ranked among the Top 5. The aggregate production of the five regions took up 76.67% of that in China.
In 2009H1, the output of Chinese pure chemical fiber cloth was 7.04 billion meters, decreasing by 0.4% YOY. The outputs of Zhejiang, Jiangsu, Fujian, Shandong and Guangdong ranked among the Top 5. The aggregate production of the five regions took up 94.20% of that in China.
In 2009H1, the output of Chinese printing and dyeing cloth was 24.227 billion meters, rising by 3.38% YOY. The outputs of Zhejiang, Jiangsu, Guangdong, Shandong and Fujian ranked among the Top 5. The aggregate production of the five regions accounted for 89.84% of that in China.
In 2009H1, the output of Chinese cord fabric was 227,700 tons, increasing by 0.37% YOY. The outputs of Jiangsu, Shandong, Zhejiang, Henan and Anhui ranked among the Top 5. The aggregate production of the five regions took up 95% of that in China.
In 2009H1, the output of Chinese yarn-dyed fabric was 919.5949 million meters, rising by 9.36% YOY. The outputs of Jiangsu, Shandong, Zhejiang, Hunan and Guangdong ranked among the Top 5. The aggregate production of the five regions took up 84.90% of that in China.

For more information please contact :

http://www.aarkstore.com/reports/Research-Report-on-Chinese-Textile-Industry-2008-2009-32797.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
http://www.aarkstore.com

Cannabis Science New Management Files First 10K Annual Report, Opens In-House Investor Relations Department in Southern Florida, and Prepares to Announce Several Expansions and Advancements for Each of Its Divisions

May 7, 2010

COLORADO SPRINGS, Colo. – Cannabis Science, Inc. (OTCBB:CBIS – News), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that it has successfully completed filing its first 10K annual report with the SEC under its new management, and that the ‘E’ has been officially removed from its OTCBB symbol. Its symbol (CBIS) is fully restored as of today.

Richard Cowan, Cannabis Science Inc., Chief Financial Officer, stated, “The delay was not the result of any substantive legal or accounting problems, but from the intricacies of reporting the financial transition in the company’s business over the last year into our current business model under Cannabis Science President and CEO Dr. Robert Melamede PhD.”

In an effort to promptly and effectively communicate the outstanding progress the Company has made, Cannabis Science has opened an in-house investor relations and public relations department in South Florida. Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman’s associates helping to cover the phones to start. Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS(2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.

Mr. Cowan concluded, “The past few months have been very positive for the Company’s expansion and progress, and several new revenue opportunities are being assessed and negotiated. The Company will be making the required announcements over the next few days outlining the new business expansions and relationships. Most of these developments result from the enormous amount of interest and communications from the media, potential partners, patients, and our outstanding and growing list of shareholders. Our new Investor Relations Department will help us tremendously in our efforts to give timely and accurate information to our shareholders and the public. Mr. Friedman and his associates are very quickly ramping up their knowledge base in regards to our past, present, and future developments so please feel free to give us a call and introduce yourself.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” “intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

CONTACT
Cannabis Science, Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888

info@cannabisscience.com

Investor Relations
Mark J. Friedman
1.877.431.CBIS
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases